share_log

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

Jin Medical International | 6-K: Report of foreign private issuer (related to financial reporting)

中進醫療 | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/07/27 04:14

Moomoo AI 已提取核心訊息

Jin Medical International reported revenue of $10.6M for H1 FY2024, up 3% YoY, while net income declined 3.5% to $1.7M. Wheelchair sales decreased 8.2% to $7.7M due to Japanese Yen weakness, while wheelchair components and other products revenue surged 52.9% to $2.9M driven by new product launches.Gross profit increased 5.8% to $3.7M with margin expanding to 35.4% from 34.4%, benefiting from higher-margin new products. Operating expenses rose 42.5% to $2.5M primarily due to increased professional fees post-IPO and expenses from newly incorporated subsidiary. Operating income declined 30.6% to $1.2M.The company maintained strong liquidity with $8.9M cash and $17.1M in short-term investments as of March 31, 2024. Management expects current cash flows, bank borrowings and IPO proceeds will be sufficient to meet working capital needs. The company continues to focus on expanding dealer networks and launching new products despite market uncertainties.
Jin Medical International reported revenue of $10.6M for H1 FY2024, up 3% YoY, while net income declined 3.5% to $1.7M. Wheelchair sales decreased 8.2% to $7.7M due to Japanese Yen weakness, while wheelchair components and other products revenue surged 52.9% to $2.9M driven by new product launches.Gross profit increased 5.8% to $3.7M with margin expanding to 35.4% from 34.4%, benefiting from higher-margin new products. Operating expenses rose 42.5% to $2.5M primarily due to increased professional fees post-IPO and expenses from newly incorporated subsidiary. Operating income declined 30.6% to $1.2M.The company maintained strong liquidity with $8.9M cash and $17.1M in short-term investments as of March 31, 2024. Management expects current cash flows, bank borrowings and IPO proceeds will be sufficient to meet working capital needs. The company continues to focus on expanding dealer networks and launching new products despite market uncertainties.
中進醫療國際報告2024財年上半年營業收入爲1060萬，較去年同期增長3%，而凈利潤下降3.5%至170萬。由於日幣貶值，輪椅銷售下降8.2%至770萬，而輪椅元件和其他產品的營業收入則因新產品發佈而激增52.9%至290萬。毛利潤增長5.8%至370萬，毛利率從34.4%擴大至35.4%，受益於新產品的高毛利。營業費用主要因IPO後專業費用增加和新成立子公司的費用上升而上升42.5%至250萬。營業收入下降30.6%至120萬。截至2024年3月31日，公司保持強勁的流動性，現金爲890萬，短期投資爲1710萬。管理層預計當前的現金流、銀行借款和IPO收益將足以滿足營運資金需求。儘管市場不確定性，公司仍繼續專注於擴大經銷商網絡和推出新產品。
中進醫療國際報告2024財年上半年營業收入爲1060萬，較去年同期增長3%，而凈利潤下降3.5%至170萬。由於日幣貶值，輪椅銷售下降8.2%至770萬，而輪椅元件和其他產品的營業收入則因新產品發佈而激增52.9%至290萬。毛利潤增長5.8%至370萬，毛利率從34.4%擴大至35.4%，受益於新產品的高毛利。營業費用主要因IPO後專業費用增加和新成立子公司的費用上升而上升42.5%至250萬。營業收入下降30.6%至120萬。截至2024年3月31日，公司保持強勁的流動性，現金爲890萬，短期投資爲1710萬。管理層預計當前的現金流、銀行借款和IPO收益將足以滿足營運資金需求。儘管市場不確定性，公司仍繼續專注於擴大經銷商網絡和推出新產品。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間